March 25th, 2015
Corline appoints former Nycomed EVP as new board member
Swedish company Corline Biomedical AB, maker and distributor of a proprietary and unique heparin coating technology for use in regenerative medicine, has appointed Kerstin Valinder-Strinnholm as non-executive member of the board of directors.
“Mrs Valinder-Strinnholm brings with her a wealth of experience of product and business development from the pharmaceutical industry which is a perfect match for Corline as we increase our focus on developing ground-breaking drug products for transplantation and cell therapies”, comments CEO Henrik Nittmar.
Kerstin Valinder-Strinnholm has more than 30 years’ experience in the pharma industry, initially focussing on sales and marketing, more recently in strategic and business development. After some 15 years in AstraZeneca, responsible for Business Strategy & Licensing for the Gastro Intestinal Division, Valinder-Strinnholm switched to Nycomed in 1999 as EVP of Corporate Development. Nycomed’s growth strategy relied on acquisitions and in-licensing of complementary technologies and products, hence Kerstin was instrumental to value building of the company. In 2011, Nycomed was acquired by Takeda for $14bn. Kerstin is now heading her own consultancy business, focussing on pharmaceutical companies.
“I am excited to join the team around Corline and to support its strategy to develop new therapeutics in the evolving field of regenerative medicine. Big Pharma has been looking for input into their development pipelines for quite some years and many people believe that it will be found in small biotech firms like the one Corline represents. I see my role in the board as one of bringing a pharma perspective to Corline’s very interesting development pipeline. As the company is rapidly approaching clinical trials, the timing is perfect”, concludes Kerstin Valinder-Strinnholm.
Back to overview